Forge Biologics assembles scientific and manufacturing advisory board

By The Science Advisory Board staff writers

May 18, 2022 -- Forge Biologics has created its new Scientific and Manufacturing Advisory Board (SMAB) filled with leaders in the field of gene therapy development and manufacturing. This independent panel represents Forge’s commitment to enhancing its gene therapy offerings through insights from experts in the field.

Among Forge's SMAB members, Steven Gray, PhD, provides expertise in adeno-associated viral (AAV) gene therapy vector engineering. Gray focuses on optimizing gene delivery into the nervous system utilizing AAV-based treatments and currently serves as the director of the University of Texas Southwestern (UTSW) Viral Vector Facility.

Robert Kotin, PhD, offers expertise in AAV gene therapy manufacturing, emphasized by his baculovirus-based AAV production system. Kotin has also headed the AAV gene therapy program at Genetic Therapy and served as a senior investigator and laboratory chief within the National Institutes of Health.

Karen Kozarsky, PhD, brings over 25 years of experience in gene therapy development to SMAB, focusing on AAV-based gene therapies for treating rare inherited disease. Furthermore, Kozarsky served as president of Vector BioPartners and a head of gene therapy within GlaxoSmithKline.

Haiyan Ma, PhD, possesses 30 years of laboratory, pharmaceutical, and research experience, with a background in molecular biology, cell and gene therapy application, virology, and DNA/RNA/protein bioanalysis. Additionally, Ma has led the establishment of a good laboratory practice compliant molecular biology lab.

Finally, Simon Waddington, PhD, contributes his research knowledge of viral and non-viral gene therapies. Waddington has been published in Cell, Nature Medicine, and Science Translational Medicine due to his work on AAV and lentivirus biology.

Forge Biologics shares plans for growth at Meeting on the Med
Chief commercial officer John Maslowski and senior vice president of business development Magdalena Tyrpien of Forge Biologics spoke with
Ray Therapeutics, Forge Biologics join forces on gene therapy
Ray Therapeutics and Forge Biologics have partnered for manufacturing that will advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001,...
Forge Biologics to present at Cell & Gene Meeting on the Mesa
Forge Biologics will deliver a presentation about its adeno-associated virus gene therapy at the upcoming Cell & Gene Meeting on the Mesa in Carlsbad,...
Forge Biologics to develop, manufacture GentiBio therapies
GentiBio and Forge Biologics have formed a strategic development and manufacturing partnership to advance GentiBio's immune tolerance platform.
Forge Biologics, Case Western train gene therapy workers
Contract development and manufacturing organization Forge Biologics and Case Western Reserve University in Cleveland announced that they will collaborate...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter